Allogene Therapeutics
ALLO
162 hedge funds and large institutions have $3.21B invested in Allogene Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 38 closing their positions.
4% more call options, than puts
Call options by funds: $5.54M | Put options by funds: $5.32M
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
2.73% less ownership
Funds ownership: 63.94% → 61.2% (-2.7%)
6% less funds holding
Funds holding: 173 → 162 (-11)
15% less capital invested
Capital invested by funds: $3.8B → $3.21B (-$585M)
24% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 38
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$23M |
| 2 |
Goldman Sachs
New York
|
+$22.1M |
| 3 |
BlackRock
New York
|
+$19.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$17M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$60.9M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$54.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$48.3M |
| 4 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$37.7M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$30.7M |
ALLO Hedge Fund Activity: Q3 2020 in Review
162 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2020, worth a combined $3.21B — down 15% from $3.8B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ALLO and 29 opened new positions — a net loss of 9 holders — while 55 trimmed existing stakes and 56 added.
The largest buyer was Capital Research Global Investors, adding an estimated $23M. The largest seller was Fidelity Investments, cutting an estimated $60.9M.
- 162 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2020, down from 173 in Q2 2020.
- Funds reported $3.21B of Allogene Therapeutics stock for Q3 2020, down 15% quarter-over-quarter.
- 29 funds opened new Allogene Therapeutics positions in Q3 2020 and 38 closed out, a net change of -9 holders.
- The largest Allogene Therapeutics buyer in Q3 2020 was Capital Research Global Investors, an estimated $23M added.
- The largest Allogene Therapeutics seller in Q3 2020 was Fidelity Investments, an estimated $60.9M sold.
Based on aggregated 13F filings for Q3 2020.